Wednesday, June 21, 2006

PT. Kalbe Farma Tbk. Annual General Meeting of Shareholders


In the year 2005, PT Kalbe Farma Tbk. (“the Company”) recorded net sales of Rp 5.87 trillion, which is an increase of 16.42% if compared to 2004’s figures. The growth is mainly contributed by the increase in volume sales of its health food’s products (Prenagen, Diabetasol, etc), gained market share of its energy drink (Extra Joss group), and volume sales of it’s OTC (Over The Counter) products (Promag, Mixagrip, Fatigon, Fatigon Spirit, etc).

The Company’s gross profit in 2005 was Rp 3.01 trillion. This is an increase of 22.91% if compared to the previous year’s figures. Noticeable improvement can be shown in the gross profit to net sales ratio; this has increased from 48.56% in 2004 to become 51.26% in 2005. The increase is mainly due to the continuous improvement effort by the Company to find areas of improvements in its production process so it can be more efficient. One such example is finding the right combination of product mix.

Marketing expenses in 2005 was Rp 1.55 trillion; this is 23.62% higher if compared to year 2004. Marketing expense to net sales ratio became 26.37% in 2005 from 24.84% in 2004. This is because of the increased effort in marketing effort to promote new as well as star products.

The Company recorded an increase in operating profit by 19.77% to become Rp 1.11 trillion from the previous year. This caused the operating profit to net sales ratio to increase from 18.32% to become 18.84%.

All these factors lead to an increased 2005 net profits of Rp 653 billion. This figure is 44.96% higher if compared to the figure in 2004. This growth can be achieved due to several reasons. Firstly, better performance in its overall operations. Secondly, interest rate was also higher on average in 2005 comparing to 2004. Finally, it is also due to the fact that Indonesian Rupiah strengthened considerably against United States Dollar.

The Company’s total asset value was Rp 4.73 trillion or an increase of 11.75% if compared to 2004. This is in line with the increased company size due to the merger which was effected on December 16, 2005.

  1. The Company’s Annual General Meeting of shareholders which was held on June 21, 2006 has resolved below matters as follows:
    1. To approve director’s annual accountability for the year ended on December 31, 2005 as well as to approve and ratify the company’s planning for year 2006;
    2. To approve and ratify the company’s yearly result for the year ended on December 31, 2005 which was audited by Public Accountant: Prasetio, Sarwoko & Sandjaja with its unqualified opinion, and to give full discharge of responsibility to the Board of Directors for their management and to the company’s Board of Commissioners for their supervision during the year ended on 31 December 2005 (acquit et de charge) as long as the results are reflected in the financial figures of Company’s yearly result for the year ended on 31 December 2005;
    3.
    a. To approve that there will be no cash dividend payout to all of Company’s shareholders;
    b. To approve that the net income in the amount of IDR 653,329,399,498 (six hundred fifty three billion three hundred twenty nine million three hundred ninety nine thousand four hundred ninety eight) is to be kept as an additional working capital for the Company;
    4.
    a. To approve the reappointment of the Board of Directors and the Board of Commissioners which will be effective starting the end of this annual general meeting of shareholders until the end of the 2008 annual general meeting of shareholders with the composition as follows:
    President Director : Johannes Setijono
    Vice President Director : Johanes Berchman Apik IbrahimVice President
    Director : Budi Dharma Wreksoatmodjo
    Director : Bernadette Ruth Irawati Setiady
    Director : Santoso Oen
    Director : Yozef Darmawan Angkasa
    Director : Vidjongtius
    Director : Herman Widjaja
    Director : Justian Sumardi
    President Commissioner : Boenjamin Setiawan
    Commissioner : Nina Gunawan
    Commissioner : Rustiyan Oen
    Independent Commissioner : Johannes Baptista Soemarlin
    Independent Commissioner : Inne Erna Adriana Soekaryo
    b. To give full authority to the meetings of the company’s Board of Commissioners to determine salary and incentive for member of Board of Commissioners and to give full authority to Board of Commissioners of the company to determine honorarium/salary for member of the company’s directors for year 2006;
    5. To give full authority to Board of Commissioners and/or Directors of the company to appoint Public Accountant listed in Capital Market Supervisory Body for auditing the company’s bookkeeping for year 2006, also to give authority to the company’s board of directors to determine their honorarium and other appointment requirements.

Source: Press Release No. 011/KFCP-DIR/PR/VI/06, dated Jun 21, 2006

BAHASA

Tuesday, June 20, 2006

PT Kalbe Farma Tbk was chosen as the Best Stock Issuer in Bisnis Indonesia Award Development Board


Attempts to be the best have to be done step by step. Whether the move is appropriate or not, we obviously need to do plenty of judgments and that inclues accepting judgments from outside parties. Recently, as published in Harian Bisnis Indonesia, Wednesday 21st June 2006, PT Kalbe Farma Tbk was chosen as the Best Stock Issuer in Bisnis Indonesia Award Development Board. Also, CEO of the Year 2006 went to Mr. Johannes Setijono, President Director of PT Kalbe Farma Tbk.

The Award was given on 20th June 2006 at Shangrila Hotel Jakarta
Sri Mulyani as the Minister of Finance stated in her opening speech that, ‘here, Asian companies are only a handful. Maybe only five (companies). I hope that the award may motivate more companies to compete in Asia.’

Bisnis Indonesia Award Winners 2006:

  • CEO of The Year: President Director of PT Kalbe Farma Tbk, Johannes Setijono
  • Best Development Board Issuer: PT Kalbe Farma Tbk
  • Best Main Board Issuer: PT Berlian Laju Tanker Tbk
  • Best Bank: PT Bank Rakyat Indonesia Tbk
  • Best Regional Development Bank: BPD Nusa Tenggara Timur
  • Best Mutual Funds: Fortis Investment
  • Most Active Security Company: PT Kim Eng Securities
  • Best Insurance (General) Company: PT Allianz Utama
  • Best Life Insurance Company: PT Sequis Life

The awards were given to urge and motivate market participants to improve and maintain their performances, 60% is based on finance load performance, 20% on corporate governance performance and 20% on corporate action performance. Particularly on corporate governance which performance is assessed based among others on: the distribution of share ownership and the level of management adherence towards law and regulations. While corporate action is based on positive activities toward the company.

Live Interview on TVRI, Friday 23rd February 2006, at 19.30 WIB
Do not miss the interview with Mr. Johannes Setijono as CEO of the Year 2006 as well as President Director of PT Kalbe Farma Tbk, the Best Stock Issuer in Bisnis Indonesia Award Development Board live from TVRI, Friday 23rd February 2006, at 19.30 WIB.

BAHASA

Wednesday, June 07, 2006

“MediFlex” Turnover Reached the Top 10 New Products in Indonesia


Mediflex, the first cream in Indonesia that contains glucosamine proves to be selling well. The cream meant for knee joint disorders is in the Top 10 New Products in Indonesia, according to the May edition of Farmacia Magazine. The definition of a new product is a product that has been launched in the last 2 years. It is in accordance with PT Kalbe Farma’s commitment to always innovate, launch (and to make it a success) new products.

Dr. Martinus Zega, Mediflex’s Product Manager affirmed that one of the keys that support the recognition of this 75gr cream is because the product is the first product in Indonesia that contains glucosamine. Another thing is because the packaging is designed to be as attractive as possible; hence, patients may know the indications or benefits of the cream. The point is still not common on medications sold as ethical drugs.

Even though it falls under the category if ethical products, the cream may be bought in pharmacies and hospitals without prescriptions. Also, the product has undergone clinical tests at Cipto Mangunkusumo Hospital Jakarta and proven to be effective.

According to the plan, after a success in Indonesia, PT Kalbe Farma Tbk will sell the product overseas.

Note
MediFlex TGC may be used to cure osteoarthritis and sport injury. MediFlex TGC is the first glucosamine cream in Indonesia. With TGC (Transdermal Glucosamine Cream) technology, hence glucosamine may penetrate the skin layer to reach the painful joint. The glucosamine level in the blood for the first 2 hours is a lot higher than oral glucosamine (administered by mouth), similarly after 6 hours. A topical application cause the chance of side effects occurring to be much smaller compared to oral administration especially one regarding gastro-intestinal problems.


The Top 10 New Products in IndonesiaAccording to Forbes, IMS Health, The Top Ten New top Products (<>

  1. Extra Joss, sachet 4gr
  2. Lipanthyl tab, 160 mg
  3. Prosogan tab, 30 mg
  4. Ezetrol tab, 10 mg
  5. Nexium vial dry, 40 mg
  6. Dexorubic in vial dry, 50 mg
  7. Mediflex cream, 75 g
  8. CDR tab eff. 10
  9. Hepsera tab 10 mg
  10. Iressa tab 250 mg

BAHASA